Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Denosumab

Amgen’s Xgeva delays prostate cancer bone pain

A clinical trial of Amgen Inc’s bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain—a finding the company believes will help boost the drug’s market potential.

Amgen said in December that monthly injections of Xgeva, also known as denosumab, added 4.2 months, compared… Amgen’s Xgeva delays prostate cancer bone pain   



risk of stone1 - intracytoplasmic sperm injection1 - attention deficit hyperactivity disorder1 - ultrasonography1 - fsgs2 - embryology1 - gamete intrafallopian transfer1 - pathologic fracture1 - prostate cancer survival1 - psa velocity1 - hyperuricosuria2 - dysmorphia1 - congenital malformations of urinary tract1 - dissolution agents1 - organ procurement and transplantation network1 - peritoneum1 - birth control pills1 - srs1 - uti7 - extracellular matrix1 - kidney disease49 - rituxan1 - patient1 - sexual abuse1 - partial nephrectomy3 - radiation nephritis1 - ket1 - urinalysis3 - high blood sugar1 - castration-resistant prostate cancer5 -